Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fully Human Anti-CD19 CAR-T Therapy for CD19+ B-cell Hematologic Malignancies
ChiCTR-OIC-17011271Phase 2Recruiting
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
- Start
- Apr 2017
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anti-CD19 CAR-T cells in B-cell hematologic malignancies, sponsored by The Affiliated Hospital of Xuzhou Medical University. Primary endpoint: Complete remission rate. Started Apr 2017; status: recruiting.
02
Drugs
anti-CD19 CAR-T cells
03
Conditions
B-cell hematologic malignancies
Beyond the preview
Go deeper on ChiCTR-OIC-17011271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OIC-17011271.